Retatrutide (LY3437943) is the first triple GLP-1/GIP/glucagon agonist approached in a phase 3 clinical trial. With a reduction in body weight reaching 24% in phase 2 studies, it surpasses in efficacy all molecules known to date in obesity research.
Science 15 min read Glossary of research peptides: essential terms from A to Z From amino acid
Tutorial (10-minute read): Calculating peptide dosage with an insulin syringe: a practical guide for research.
COMPARATIVE GUIDE Research on GLP-1 peptides has evolved rapidly in recent years: from the monoagonist Semaglutide
Science 12 min read Peptide stability: degradation factors and preservation strategies Peptides are
Science 14 min read How the GLP-1 receptor works: molecular mechanisms and research implications The GLP-1 receptor
Comparative analysis (11 min read) Peptides vs. SARMs: fundamental differences in research Peptides and SARMs are two categories of
Comparison (11 min read) GHK-Cu vs BPC-157: Which repair peptide for which research? GHK-Cu and
Peptide Guide 12 min read Ipamorelin: The Selective GH Secretagogue — Complete Scientific Guide Third-stage Synthetic Pentapeptide
Peptide Guide 12 min read Semax: Nootropic and Neuroprotective Peptide — Complete Scientific Guide Synthetic Analogue of the fragment
